The medical records of patients with infl ammatory bowel disease (IBD) who had HACA and infl iximab concentrations measured were reviewed to determine whether the result affected clinical management.
INTRODUCTION
Infl iximab (Remicade, Centocor, Horsham, PA) is a chimeric monoclonal IgG1 antibody against tumor necrosis factor (TNF) that is eff ective for the treatment of Crohn ' s disease and ulcerative colitis ( 1 -3 ) . Treatment with infl iximab can result in immunogenicity and the formation of human anti-chimeric antibodies (HACAs), also known as antibodies to infl iximab ( 4 ) . Th e incidence of HACAs has been shown to be as high as 37 -61 % in patients receiving episodic infl iximab ( 4 ) . Scheduled infl iximab therapy decreases the incidence of HACAs to 6 -16 % ( 2,5 ). Concomitant immunosuppressive therapy also decreases the formation of HACAs, but this may only be important in those receiving episodic therapy ( 2,4 -9 ) . Immunogenicity to infl iximab is not a unique phenomenon related to its chimeric structure, as treatment with any exogenous protein can lead to the development of antibodies ( 10, 11 ) . In fact, similar rates of antibodies have been reported in patients treated with adalimumab and certolizumab pegol ( 12 -15 ) .
Some have questioned whether the presence of antibodies to anti-TNF agents directly correlates with decreased effi cacy ( 16 ) . Comparisons can be drawn from the rheumatoid arthritis literature. Several groups have shown that the development of antibodies to infl iximab and adalimumab correlates with not only decreased drug concentrations but also decreased clinical response ( 17 -21 ) . In infl ammatory bowel disease (IBD), studies have shown that there is a shorter duration of clinical response in patients with detectable HACA concentrations ( 4, 22, 23 ) . A subgroup analysis of a larger randomized controlled trial showed a trend toward decreased remission in patients who underwent episodic therapy and had detectable antibodies ( 6 ) . Th e clinical effi cacy of infl iximab may be dependent not only on the absence of HACA but also on infl iximab concentrations. In a study of Crohn ' s disease patients on scheduled maintenance infl iximab therapy, patients with detectable trough concentrations had a higher rate of clinical remission, a lower serum C-reactive protein (CRP) concentration, and a higher rate of endoscopic improvement ( 5 ). HACAs have also been associated with an increased risk of infusion reactions, which in turn can also lead to decreased infliximab concentrations ( 4 -6,23,24 ) .
Clinical Utility of Measuring Infl iximab and Human
Although the associations between clinical effi cacy and infusion reactions with infl iximab concentrations and HACA status have been described, the clinical utility of these tests in routine practice remains unclear. Th e clinical indications for measuring HACA and infl iximab concentrations in patients with IBD have not been previously assessed. Furthermore, the optimal patient management based on the results of testing has not been clearly elucidated. We retrospectively studied the utility of measuring HACA and infl iximab concentrations and compared subsequent clinical management and response. We propose a treatment algorithm based on the results of testing.
METHODS

Overview
We conducted a retrospective review of the medical records of all patients at our institution who underwent HACA and infl iximab concentration testing. No systematic strategy was used to test all patients who were failing or who were intolerant to infl iximab. Physicians working in the Infl ammatory Bowel Disease Clinic at Mayo Clinic, Rochester can, at their discretion, order HACA and infl iximab concentrations as a send-out test from Mayo Medical Laboratories to Prometheus Laboratories (San Diego, CA). Medical records were electronically searched to identify patients who had received infl iximab and who underwent testing for HACA and infl iximab concentrations between 1 January 2003 and 1 August 2008. All patients included in the analysis had provided authorization for medical record review for research purposes, and the study was approved by the Mayo Clinic Institutional Review Board.
Inclusion and exclusion criteria
All patients with a diagnosis of Crohn ' s disease, ulcerative colitis, or indeterminate colitis who were treated with infl iximab and underwent HACA and infl iximab concentration testing were included in the study. Exclusion criteria were limited to: the absence of follow-up aft er being tested, and the infusion of infl iximab as a part of a clinical trial.
Measures and analyses
Demographic and clinical characteristics were abstracted from the electronic medical record in those patients that met entry criteria. Characteristics included age, gender, smoking status, type of IBD, anatomic distribution, duration of disease, previous surgery, prior and concurrent treatment for IBD, date of infliximab initiation, dose, duration of treatment, clinical response, change in dose or frequency, acute or delayed hypersensitivity reactions, autoimmune reactions, and change to another anti-TNF agent. Acute infusion reactions were defined as an adverse event that occurred within 1 h after infusion. Delayed hypersensitivity reactions were defined as the occurrence of myalgias, arthralgias, fever, or rash occurring 1 -14 days after infusion. Clinical response was retrospectively determined as defined earlier ( 25 ) . In patients with Crohn ' s disease, complete response was defined as cessation of diarrhea and abdominal cramping, or, in the cases of patients with fistulas, cessation of fistula drainage and complete closure of all draining fistulas. Partial response was defined as a reduction in the amount of diarrhea and abdominal cramping, or, in the case of fistula patients, a decrease in the drainage, size, or number of fistulas. Outcomes not meeting one of the above definitions were classified as non-response ( 25 ) . In patients with ulcerative colitis, complete response was defined as cessation of diarrhea, hematochezia, and abdominal cramping whereas partial response was defined as a reduction in the amount of diarrhea, hematochezia, and abdominal cramping. The results of radiological and / or endoscopic imaging were documented when available.
Th e testing date, the reason for testing, and the rationale for changing treatment post-testing were obtained from the medical record. Results of HACA and infl iximab concentration testing from Prometheus Laboratories were categorized in the following manner. Infl iximab concentrations ≥ 12 mcg / ml at 4 weeks aft er infusion were considered therapeutic ( 4 ). Patients with a detectable infl iximab concentration ( > 1.4 mcg / ml) at dosing trough were considered to have therapeutic concentrations ( 5 ) . Patients with any detectable HACA concentration were considered to have a positive antibody status and by defi nition, had an undetectable infl iximab concentration (the presence of infl iximab in the sample interferes with the HACA assay).
Subtherapeutic infl iximab concentrations were defi ned as an undetectable trough concentration or an infl iximab concentration < 12 mcg / ml at 4 weeks aft er infusion. Testing results that were non-interpretable because testing was performed at an inappropriate time were not included in the analysis (e.g., infl iximab concentration > 12 mcg / ml before 4 weeks or < 12 mcg / ml aft er 4 weeks, but before trough dosing). Clinical response (as defi ned above) to any change in therapeutic treatment was also assessed. C-reactive protein and erythrocyte sedimentation rate at initiation of infl iximab, before change in treatment, and posttreatment were abstracted when data were available.
Th e clinical utility of testing was assessed retrospectively. A priori , we determined that when the results of testing changed treatment or helped to avoid inappropriate clinical management,
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the test was considered useful. Testing was considered to have no impact on clinical decision making when a counterintuitive treatment plan was instituted, for example, when the treating clinicians: dose-increased infl iximab when HACAs were detected, maintained the same therapy when subtherapeutic infl iximab concentrations were found and either dose-increased infl iximab or changed anti-TNF agents when therapeutic infl iximab concentrations were detected.
Statistical analysis
Descriptive statistics were used to analyze baseline characteristics. Fisher ' s exact test, χ 2 test, and log-rank test for discontinuation were used for statistical analysis between groups. A P value of 0.05 was considered signifi cant. Statistical analyses were conducted using Statistical Analysis Soft ware (SAS).
RESULTS
Patient characteristics
One hundred fi ft y-fi ve patients underwent HACA and infl iximab concentration testing between 1 January 2003 and 1 August 2008. One hundred twelve patients (71.8 % ) of the initial tests were ordered by a single physician (W.J.S.). Th e baseline demographic and clinical characteristics are shown in Table 1 . One hundred twenty-seven patients (82 % ) received induction followed by scheduled dosing. Among the 28 patients who did not receive induction dosing, 18 (64 % ) subsequently received scheduled dosing. Forty-seven percent of patients were on concurrent immunosuppressant medication consisting of azathioprine, 6-mercaptopurine, or methotrexate. Th e median time to initial testing aft er infl iximab initiation was 50 weeks (interquartile ratio [IQR]: 22.7 -120), and the median number of infusions (per patient) before testing was 8 (IQR: 4 -15). Initial complete clinical response to infl iximab therapy was seen in 100 patients (65 % ), partial response was observed in 45 patients (29 % ), and no response was seen in 10 patients (6 % ). Forty-three patients (28 % ) had the dose or frequency of infl iximab increased before testing. Th e results of testing stratifi ed by the presence or absence of concomitant immunosuppressive therapy are summarized in Table 2 . Concurrent immunosuppressive therapy was significantly associated with negative HACA status (14 % in those on concomitant immunosuppressive therapy vs. 29 % in those not, P < 0.032), as well as therapeutic infl iximab concentrations (48 % vs. 21 % , P < 0.001). HACA status did not signifi cantly diff er in patients receiving scheduled dosing compared with episodic treatment, but only 10 patients (6 % ) were receiving episodic treatment.
Indications for testing
Th e indications for testing are listed in Table 3 . Th e main indications for initial testing were: loss of response to infl iximab (49 % ), partial response aft er initiation of infl iximab (22 % ), Table 5 . Th irty-fi ve patients were positive for HACAs. Among the 12 HACA-positive patients who changed to another anti-TNF agent, a complete or partial response was noted in 11 (92 % ) ( Table 6 ). On the other hand, increasing the dose of infl iximab in 6 HACApositive patients was associated with response in 1 patient (17 % , P < 0.004). During subsequent testing, none of these patients achieved therapeutic infl iximab concentrations with dose escalation. Of the remaining patients, six discontinued infl iximab, three continued on the same dose, three proceeded to surgery, and fi ve patients could not be assessed as adequate follow-up information was not available.
Sixty-three patients had subtherapeutic infl iximab concentrations. Among 29 patients with subtherapeutic infl iximab concentrations, increasing the infl iximab dose was associated with complete or partial clinical response in 25 (86 % ). Six patients with subtherapeutic infl iximab concentrations were changed to another anti-TNF, and this was associated with a response in two patients (33 % , P < 0.016). Of the remaining patients, 10 continued on the same dose, 9 discontinued infl iximab, 8 proceeded to surgery, and 7 patients could not be assessed as adequate follow-up information was not available.
Fift y-one patients had therapeutic infl iximab concentrations. In 21 situations where patients had clinical symptoms and therapeutic infl iximab concentrations, and radiological and / or endoscopic imaging was available, patients had no evidence of active infl ammation 62 % of the time (95 % CI: 38 -82 % ), and continued at the same dose 76 % (95 % CI: 54 -90 % ). In the eight patients (38 % ) that had active infl ammation despite therapeutic infl iximab concentrations, three patients continued on the same dose, two patients had surgery, two patients were changed to another anti-TNF (no follow-up information available), and one was treated with an additional immunosuppressive agent.
In 5 patients evaluated for acute infusion reactions, 1 patient (20 % ; 95 % CI: 2 -64 % ) had detectable HACAs, whereas among 16 patients assessed for delayed hypersensitivity or autoimmune reactions, 6 had detectable antibody concentrations (38 % ; 95 % CI: 18 -61 % ). In the seven patients assessed before possible reintroduction of infl iximab aft er a drug holiday, six patients (86 % ) had detectable HACAs.
Infl iximab discontinuation
By the end of the study period (August 2008), among 140 patients with available information, 51 were still on infl iximab (36 % ; 95 % CI: 29 % -45). Th e main indications for infl iximab discontinuation were loss of response in 38 patients (27 % ; 95 % CI: 20 -35 % ) and continued partial response in 20 (14 % ; 95 % CI: 9 -21 % ). Other indications for infl iximab discontinuation (all < 10 % ) were primary non-response, surgical intervention, autoimmune or delayed hypersensitivity reaction, infusion reactions, or other side-eff ects. In patients with therapeutic infl iximab concentra- 
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and infliximab concentrations could lead to a more nuanced approach, but the use of these tests in clinical practice has not been reported. Our study shows that measurement of HACA and infl iximab concentrations is useful in clinical practice. Th e patients in our study were tested, on average, approximately 1 year aft er the initiation of infl iximab. Th e majority of tests were performed for loss of response or partial clinical response (71 % ) and in these patients 62 % had detectable HACAs or non-therapeutic infl iximab concentrations. It is in this cohort of patients that the test results are most important in determining appropriate treatment. When ordering HACA and infl iximab concentrations, there are three possible permutations ( Figure 1 ) .
Th e presence of HACAs provides clear evidence that immunogenicity to infl iximab has developed and that further treatment would result in a decreased clinical response or possible infusion reactions ( 4 -6,16,22,23 ) . Similar to the study by Maser et al. ( 5 ) , patients with any detectable HACA concentration were considered to have a positive antibody status because they likely have developed some degree of immunogenicity to infl iximab. In our study, a change to another anti-TNF agent in HACA-positive patients was associated with a complete or partial response in 92 % , whereas increasing the dose of infl iximab resulted in a 17 % response ( P < 0.004). Th is would suggest that increasing the infl iximab dose in the face of positive HACA is unlikely to be a successful strategy, and the results of HACA testing are indeed useful in this cohort of patients.
In patients with subtherapeutic concentrations, infl iximab dose escalation was associated with a signifi cantly increased clinical response compared with changing to another anti-TNF (86 % vs. 33 % , P < 0.016). In addition, patients with therapeutic infl iximab concentrations who continued the same dose and those with subtherapeutic concentrations who were dose escalated had a similar median time to infl iximab discontinuation (75 weeks). Th ese results suggest that increasing the infl iximab dose may be a successful strategy in treating patients with subtherapeutic concentrations. At present, there are no comparative eff ectiveness studies assessing dose escalation vs. changing to another anti-TNF agent, in patients that lose response to infliximab. Previous exposure to an anti-TNF agent is associated with a reduced clinical response to a second anti-TNF agent compared with anti-TNF naive patients and this could perhaps explain the increased clinical response rate seen with dose intensifi cation in our study ( 31 ) . Both strategies are likely eff ective and further studies need to be performed to determine whether one treatment strategy is superior to the other.
A 4-week post-infusion infl iximab concentration of > 12 mcg / ml and a detectable trough concentration have both been found to be signifi cantly associated with decreased infusion reactions, increased clinical remission, lower C-reactive protein, and endoscopic healing ( 4, 5 ) . In the presence of therapeutic infl iximab concentrations and clinical symptoms, confi rmatory testing with ileocolonoscopy and / or computed tomography or magnetic resonance imaging enterography should be performed. To underscore this recommendation, in patients with clinical symptoms tions who continued the same dose and those with subtherapeutic concentrations who were dose escalated, the median time to discontinuation of infl iximab aft er the test date was similar at 75 weeks (IQR: 46 -116 and 45 -92, respectively, P > 0.61).
DISCUSSION
Infliximab has become a common treatment for both Crohn ' s disease and ulcerative colitis. Among patients who initially respond to infliximab, up to 40 % will subsequently lose response ( 2 ) . The clinical management of patients who respond to infliximab and then lose response remains largely empiric. Management strategies include escalation of the dose or shortening of the infusion interval, switching to another anti-TNF agent, or switching to another therapeutic class ( 26 -29 ) . A decision analysis suggested that dose escalation was more likely to be effective than switching drugs within the class, but this empiric strategy likely leads to dose escalation in some patients who are HACA positive ( 30 ) . It is logical that the incorporation of routine measurement of HACA CTE, computed tomography enterography; HACA, human anti-chimeric antibody; TNF, tumor necrosis factor. a These included delayed hypersensitivity reactions ( n = 4), tuberculosis ( n =1), and lymphoma ( n =1). and a therapeutic infl iximab concentration, patients continued at the same dose 76 % of the time and had no evidence of active infl ammation by endoscopic / radiographic assessment 62 % of the time. Increasing the dose or changing to another anti-TNF agent in these patients would have led to inappropriate management. If therapeutic infl iximab concentrations are present and there is persistent disease, then increasing the dose of infl iximab or changing to another anti-TNF with the same mechanism of action would likely be of little benefi t, and consideration should be given to switching to a medication with a diff erent mechanism of action. In this cohort of patients, infl iximab concentration testing would be clinically useful and would help to avoid inappropriate management. Although 10 % of HACA and infliximab concentration testing was completed to assess for delayed hypersensitivity reactions (HACAs detected in only 38 % of patients), there is little data to support a link between antibody presence and these reactions. In the study by Baert et al. ( 4 ) , there was no relationship between delayed hypersensitivity reactions and HACA concentrations. On the other hand, testing before retreatment with infliximab may be more useful as HACAs were detectable in 86 % of these patients in our study. Similarly, in a study published in abstract form, all patients with Crohn ' s disease who were retreated with infliximab after a drug holiday and developed a delayed hypersensitivity reaction had detectable HACAs after infusion ( 32 ) .
Patients receiving concurrent immunosuppressive therapy were significantly more likely to have therapeutic infliximab concentrations and less likely to have detectable antibodies, as compared with those not receiving concomitant immunosuppressive therapy. These results should be interpreted with caution given that this is a retrospective study. There are also several other potential limitations to this study. Patient selection for testing was at the discretion of the treating physician, and the resultant cohort of patients represent only a small subset of the total population of patients on infliximab at Mayo Clinic. Clinical response was abstracted through review of patient charts using pre-defined clinical criteria. Validated instruments such as the Crohn ' s Disease Activity Index, Harvey-Bradshaw Index, and endoscopic improvement could not be obtained retrospectively. In addition, there is no specific comparator / control group in which no testing was performed and so absolute conclusions regarding the superiority of testing over clinical judgment alone cannot be made. However, the results of this study do suggest that testing in specific circumstances could potentially help to avoid inappropriate management.
In conclusion, our data suggest that HACA and infl iximab concentration testing impact treatment decisions in 73 % of patients and that these tests are a useful adjunct to clinical and endoscopic / radiological assessment. Use of these tests can potentially avoid inappropriate management and optimize patient treatment algorithms ( Figure 1 ) . A prospective randomized trial should be conducted to confi rm these fi ndings. 
CONFLICT OF INTEREST
Guarantor of the article: Waqqas Afi f, MD. Specifi c author contributions: Study design, data collection, statistical analysis, and writing of the draft manuscript: Waqqas Afi f; study design, data collection, statistical analysis, and critical revision of the manuscript: Edward Loft us; data collection and critical revision of the manuscript: William Faubion; data collection and critical revision of the manuscript: Sunanda Kane; data collection and critical revision of the manuscript: David Bruining; data collection: Karen Hanson; study design, data collection, statistical analysis, and critical revision of the paper: William Sandborn. All authors approved the fi nal submission. Financial support: None. This strategy may be preferable. HACA, human anti-chimeric antibody; TNF, tumor necrosis factor.
